Home > Members > Miloud Kaddar

Miloud Kaddar

Health economist, Independent consultant.

> mkaddar@hotmail.com

Senior health economist with more than twenty five years of experience in international health, population, and development, Miloud Kaddar joined WHO-HQ in November 2002. As principal adviser, he led a group working on vaccine and biological products procurement, health financing and global interdependence. His principal assignments include work on supply, procurement strategies and policies, costing, pricing and financing of immunization and public health programs, health system development, middle income countries and financial sustainability issues.
Prior to joining WHO, he was serving as senior adviser to the Ministry of Health in Morocco in implementing an EU supported project on health sector reform. He also worked for Abt Associates in Bethesda (USA) to providing the technical leadership to the Partnership for Health Reform’s (PHR) Special Initiative on capacity building and Sustainability of Immunization Programs. He held a chief of department position in the International Children Centre in Paris for almost 10 years. He has conducted related health policy research, health program assessments and pharmaceutical sector policies and activities for UNICEF, WHO, UNDP, the World Bank, the EU and GTZ. He has served on the economics faculties of the various Universities in the world. He is one of the founders of the Maghreb Network on health economics and health Systems (RESSMA) and an active member of the African Health Economics and Policy Association (AfHEA). Mr. Kaddar has a Post Graduate Degree in Economics from the University of Oran in Algeria, a Master of Arts from University of Grenoble (France) and a Diploma on Public Health from the University of Nancy in France. He is the author of more than 25 articles and other publications on health system financing and management, economics of pharmaceutical sector and vaccines, capacity building in public health and health economics.


Shelabya A., Abdul Rahim H., Abul Naga R., Awawda S., Mataria A., Abu-Zaineh M., Farag M. and Kaddar M Covid-19: Public policy responses and health consequences in the Arab region. Hikama, 1: 141-156.

Hinsch, M., Kaddar, M., & Schmitt, S. (2014) Enhancing medicine price transparency through price information mechanisms. Global Health, 10, 34.

Kaddar, M., Milstien, J., & Schmitt, S. (2014) Impact of BRICS' investment in vaccine development on the global vaccine market. Bulletin of the World Health Organization, 92(6), 436-446.

Saxenian, H., Hecht, R., Kaddar, M., Schmitt, S., Ryckman, T., & Cornejo, S. (2014) Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries. Health Policy and Planning, czu003.

Kaddar M., Schmitt S., Makinen M., & Milstien J. (2013) Global support for new vaccine implementation in middle-income countries. Vaccine, 31, B81-B96.

Makinen, M., Kaddar, M., Molldrem, V., & Wilson, L. (2012) New vaccine adoption in lower-middle-income countries. Health Policy and Planning, 27(suppl 2), ii39-ii49.

Hecht, R., Kaddar, M., & Schmitt, S. (2011) Transparent pricing of vaccines would help poor as well as rich countries. BMJ, 343:d7414. 

Levin, A., & Kaddar, M. (2011) Role of the private sector in the provision of immunization services in low-and middle-income countries. Health Policy and Planning, 26(suppl 1), i4-i12.

Zuber, P. L., El-Ziq, I., Kaddar, M., Ottosen, A. E., Rosenbaum, K., Shirey, M., et al. (2011) Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine, 29(17), 3149-3154.

Chougrani, S., & Kaddar, M. (2010) Expérience de la contractualisation dans le secteur de la santé en Algérie. Journal de Gestion et d'Economie Médicales, 28(5), 179-193.

Milstien, J. B., & Kaddar, M. (2010) The role of emerging manufacturers in access to innovative vaccines of public health importance. Vaccine, 28(9), 2115-2121.

El-Idrissi, D. Z. E., Miloud, K., & Belgacem, S. (2008) Constraints and obstacles to social health protection in the Maghreb: the cases of Algeria and Morocco. Bulletin of the World Health Organization, 86(11), 902-904.

Kaddar M. (2019) Ongoing transition in Maghreb Health Systems: Sustainability of tentative support from external partners (donors, EU and UN agencies). European Journal of Public Health,Vol. 29, Supplement 4.

Kaddar M, Saxenian H and al.(2019) Vaccine procurement in the Middle East and North Africa region: Challenges and ways of improving program efficiency and fiscal space. Vaccine. Volume 37, Issue 27, Pages 3520-3528.

Kaddar M.(2019) Market access for innovative medicines in Algeria: The case of oncology drugs. Algerian Journal of Health Sciences. Vol. 01.

Saxenian H, Sadr-Azodi N, Kaddar M, et al (2019) Immunization financing and programme performance in the Middle East and North Africa, 2010 to 2017. BMJ Global Health.

Hecht R., Kaddar M, and al (2018) Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action. Journal of Global Health Reports.

Sloane P. and Kaddar M. (2018) Health Trends in the Middle East and North Africa A Regional Overview of Health Financing and the Private Health Sector. SHOPS Plus and HFG.

Kaddar M. et al. (2018) Immunization Financing in MENA Middle-Income Countries. UNICEF MENA.